UAB Digital Repository of Documents 4 records found  Search took 0.00 seconds. 
1.
22 p, 5.2 MB Chromatin regulation by Histone H4 acetylation at Lysine 16 during cell death and differentiation in the myeloid compartment / Urdinguio, R.G. (Cancer Epigenetics Laboratory. Institute of Oncology of Asturias (IUOPA). ISPA-Hospital Universitario Central de Asturias HUCA. Universidad de Oviedo) ; Lopez, V. (Nanomaterials and Nanotechnology Research Center (CINN-CSIC). Universidad de Oviedo-Principado de Asturias) ; Bayón, G.F. (Cancer Epigenetics Laboratory. Institute of Oncology of Asturias (IUOPA). ISPA-Hospital Universitario Central de Asturias HUCA. Universidad de Oviedo) ; Díaz de la Guardia, Rafael (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Sierra, M.I. (Cancer Epigenetics Laboratory. Institute of Oncology of Asturias (IUOPA). ISPA-Hospital Universitario Central de Asturias HUCA. Universidad de Oviedo) ; García-Toraño, E. (Cancer Epigenetics Laboratory. Institute of Oncology of Asturias (IUOPA). ISPA-Hospital Universitario Central de Asturias HUCA. Universidad de Oviedo) ; Perez, R.F. (Cancer Epigenetics Laboratory. Institute of Oncology of Asturias (IUOPA). ISPA-Hospital Universitario Central de Asturias HUCA. Universidad de Oviedo) ; García, M.G. (Cancer Epigenetics Laboratory. Institute of Oncology of Asturias (IUOPA). ISPA-Hospital Universitario Central de Asturias HUCA. Universidad de Oviedo) ; Carella, A. (Cancer Epigenetics Laboratory. Institute of Oncology of Asturias (IUOPA). ISPA-Hospital Universitario Central de Asturias HUCA. Universidad de Oviedo) ; Pruneda, P.C. (Cancer Epigenetics Laboratory. Institute of Oncology of Asturias (IUOPA). ISPA-Hospital Universitario Central de Asturias HUCA. Universidad de Oviedo) ; Prieto, C. (Cancer Epigenetics Laboratory. Institute of Oncology of Asturias (IUOPA). ISPA-Hospital Universitario Central de Asturias HUCA. Universidad de Oviedo) ; Dmitrijeva, M. (Cancer Epigenetics Laboratory. Institute of Oncology of Asturias (IUOPA). ISPA-Hospital Universitario Central de Asturias HUCA. Universidad de Oviedo) ; Santamarina, P. (Cancer Epigenetics Laboratory. Institute of Oncology of Asturias (IUOPA). ISPA-Hospital Universitario Central de Asturias HUCA. Universidad de Oviedo) ; Belmonte, T. (Cancer Epigenetics Laboratory. Institute of Oncology of Asturias (IUOPA). ISPA-Hospital Universitario Central de Asturias HUCA. Universidad de Oviedo) ; Mangas, C. (Cancer Epigenetics Laboratory. Institute of Oncology of Asturias (IUOPA). ISPA-Hospital Universitario Central de Asturias HUCA. Universidad de Oviedo) ; Diaconu, E. (Cancer Epigenetics Laboratory. Institute of Oncology of Asturias (IUOPA). ISPA-Hospital Universitario Central de Asturias HUCA. Universidad de Oviedo) ; Ferrero, C. (Cancer Epigenetics Laboratory. Institute of Oncology of Asturias (IUOPA). ISPA-Hospital Universitario Central de Asturias HUCA. Universidad de Oviedo) ; Tejedor, J.R. (Cancer Epigenetics Laboratory. Institute of Oncology of Asturias (IUOPA). ISPA-Hospital Universitario Central de Asturias HUCA. Universidad de Oviedo) ; Fernandez-Morera, J.L. (Cancer Epigenetics Laboratory. Institute of Oncology of Asturias (IUOPA). ISPA-Hospital Universitario Central de Asturias HUCA. Universidad de Oviedo) ; Bravo, C. (Cancer Epigenetics Laboratory. Institute of Oncology of Asturias (IUOPA). ISPA-Hospital Universitario Central de Asturias HUCA. Universidad de Oviedo) ; Bueno, Clara (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Sanjuan-Pla, A. (Hematology Research Group. Instituto de Investigación Sanitaria la Fe (IIS la Fe)) ; Rodriguez, R.M. (Translational Immunology Laboratory. Instituto de Investigación Sanitarias Del Principado de Asturias (ISPA). Immunology Department. Hospital Universitario Central de Asturias (HUCA)) ; Suarez-Alvarez, B. (Translational Immunology Laboratory. Instituto de Investigación Sanitarias Del Principado de Asturias (ISPA). Immunology Department. Hospital Universitario Central de Asturias (HUCA)) ; López-Larrea, C. (Translational Immunology Laboratory. Instituto de Investigación Sanitarias Del Principado de Asturias (ISPA). Immunology Department. Hospital Universitario Central de Asturias (HUCA)) ; Bernal, T. (Servicio de Hematología. Hospital Universitario Central de Asturias (HUCA)) ; Colado, E. (Servicio de Hematología. Hospital Universitario Central de Asturias (HUCA)) ; Balbín, M. (Service of Molecular Oncology. Hospital Universitario Central de Asturias. Instituto Universitario de Oncología Del Principado de Asturias. Universidad de Oviedo) ; García-Suarez, O. (Department of Morphology and Cellular Biology. Faculty of Medicine. University of Oviedo) ; Chiara, M.D. (Otorhinolaryngology Service. Hospital Universitario Central de Asturias. Instituto Universitario de Oncología Del Principado de Asturias. Universidad de Oviedo. CIBERONC) ; Sáenz-De-Santa-María, I. (Otorhinolaryngology Service. Hospital Universitario Central de Asturias. Instituto Universitario de Oncología Del Principado de Asturias. Universidad de Oviedo. CIBERONC) ; Rodríguez, F. (Departamento de Bioquímica y Biología Molecular. Facultad de Medicina. Instituto Universitario de Oncología (IUOPA). Universidad de Oviedo) ; Pando-Sandoval, A. (Hospital Universitario Central de Asturias (HUCA). Instituto Nacional de Silicosis (INS). Área Del Pulmón. Facultad de Medicina. Universidad de Oviedo) ; Rodrigo, L. (Hospital Universitario Central de Asturias (HUCA). Gastroenterology Service. Facultad de Medicina. Universidad de Oviedo) ; Santos, L. (Fundación para la Investigación Biosanitaria de Asturias (FINBA). Instituto de Investigación Sanitaria Del Principado de Asturias (ISPA)) ; Salas, A. (Cytometry Service. Servicios Científico-Técnicos (SCTs). Universidad de Oviedo) ; Vallejo-Díaz, J. (Department of Immunology and Oncology. National Center for Biotechnology. CNB-CSIC) ; C Carrera, A. (Department of Immunology and Oncology. National Center for Biotechnology. CNB-CSIC) ; Rico, D. (Institute of Cellular Medicine. Newcastle University) ; Hernández-López, I. (Institute of Cellular Medicine. Newcastle University) ; Vayá, A. (Hemorheology and Haemostasis Unit. Service of Clinical Pathology. La Fe University Hospital) ; Ricart, J.M. (Dermatology Service. Quirón Clinic) ; Seto, E. (George Washington University Cancer Center. Department of Biochemistry and Molecular Medicine. George Washington University) ; Sima-Teruel, N. (Chromatin Biology Laboratory. Cancer Epigenetics and Biology Program (PEBC). Bellvitge Biomedical Research Institute (IDIBELL)) ; Vaquero, Alejandro (Chromatin Biology Laboratory. Cancer Epigenetics and Biology Program (PEBC). Bellvitge Biomedical Research Institute (IDIBELL)) ; Valledor, L. (Plant Physiology Lab. Department of Organisms and Systems Biology. Faculty of Biology. University of Oviedo) ; Cañal, M.J. (Plant Physiology Lab. Department of Organisms and Systems Biology. Faculty of Biology. University of Oviedo) ; Pisano, D. (Bioinformatics Unit. Structural Biology and Biocomputing Program. Spanish National Cancer Research Center (CNIO)) ; Graña-Castro, O. (Bioinformatics Unit. Structural Biology and Biocomputing Program. Spanish National Cancer Research Center (CNIO)) ; Thomas, T. (Walter and Eliza Hall Institute of Medical Research. Department of Medical Biology. University of Melbourne) ; Voss, A.K. (Walter and Eliza Hall Institute of Medical Research. Department of Medical Biology. University of Melbourne) ; Menéndez, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Villar-Garea, A. (R and D. Sanofi-Aventis Deutschland GmbH. Industriepark Höchst Building G878) ; Deutzmann, R. (Institute of Biochemistry. Genetics and Microbiology. University of Regensburg) ; Fernandez, A.F. (Cancer Epigenetics Laboratory. Institute of Oncology of Asturias (IUOPA). ISPA-Hospital Universitario Central de Asturias HUCA. Universidad de Oviedo) ; Fraga, M.F. (Nanomaterials and Nanotechnology Research Center (CINN-CSIC). Universidad de Oviedo-Principado de Asturias) ; Universitat Autònoma de Barcelona
Histone H4 acetylation at Lysine 16 (H4K16ac) is a key epigenetic mark involved in gene regulation, DNA repair and chromatin remodeling, and though it is known to be essential for embryonic development, its role during adult life is still poorly understood. [...]
2019 - 10.1093/nar/gkz195
Nucleic acids research, Vol. 47 Núm. 10 (april 2019) , p. 5016-5037  
2.
22 p, 7.9 MB Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program / Janin, M. (Cancer Epigenetics and Biology Program (PEBC). Bellvitge Biomedical Research Institute (IDIBELL). L'Hospitalet) ; Ortiz-Barahona, V. (Cancer Epigenetics and Biology Program (PEBC). Bellvitge Biomedical Research Institute (IDIBELL). L'Hospitalet) ; de Moura, M.C. (Cancer Epigenetics and Biology Program (PEBC). Bellvitge Biomedical Research Institute (IDIBELL). L'Hospitalet) ; Martínez-Cardús, A. (Cancer Epigenetics and Biology Program (PEBC). Bellvitge Biomedical Research Institute (IDIBELL). L'Hospitalet) ; Llinàs-Arias, P. (Cancer Epigenetics and Biology Program (PEBC). Bellvitge Biomedical Research Institute (IDIBELL). L'Hospitalet) ; Soler, Marta (Cancer Epigenetics and Biology Program (PEBC). Bellvitge Biomedical Research Institute (IDIBELL). L'Hospitalet) ; Nachmani, D. (Department of Medicine and Pathology. Cancer Research Institute. Beth Israel Deaconess Cancer Center. Beth Israel Deaconess Medical Center. Harvard Medical School) ; Pelletier, J. (Molecular Mechanisms and Experimental Therapy in Oncology Program. Metabolism and Cancer Group. Bellvitge Biomedical Research Institute (IDIBELL). L'Hospitalet) ; Schumann, U. (EMBL-Australia Collaborating Group. Department of Genome Sciences. The John Curtin School of Medical Research. The Australian National University) ; Calleja-Cervantes, M.E. (Cancer Epigenetics and Biology Program (PEBC). Bellvitge Biomedical Research Institute (IDIBELL). L'Hospitalet) ; Moran, Sebastian (Cancer Epigenetics and Biology Program (PEBC). Bellvitge Biomedical Research Institute (IDIBELL). L'Hospitalet) ; Guil, S. (Cancer Epigenetics and Biology Program (PEBC). Bellvitge Biomedical Research Institute (IDIBELL). L'Hospitalet) ; Bueno-Costa, A. (Cancer Epigenetics and Biology Program (PEBC). Bellvitge Biomedical Research Institute (IDIBELL). L'Hospitalet) ; Piñeyro, D. (Cancer Epigenetics and Biology Program (PEBC). Bellvitge Biomedical Research Institute (IDIBELL). L'Hospitalet) ; Perez-Salvia, M. (Cancer Epigenetics and Biology Program (PEBC). Bellvitge Biomedical Research Institute (IDIBELL). L'Hospitalet) ; Rosselló-Tortella, M. (Cancer Epigenetics and Biology Program (PEBC). Bellvitge Biomedical Research Institute (IDIBELL). L'Hospitalet) ; Piqué, L. (Cancer Epigenetics and Biology Program (PEBC). Bellvitge Biomedical Research Institute (IDIBELL). L'Hospitalet) ; Bech-Serra, J.J. (Proteomics Unit. Bellvitge Biomedical Research Institute (IDIBELL). L'Hospitalet) ; De La Torre, C. (Proteomics Unit. Bellvitge Biomedical Research Institute (IDIBELL). L'Hospitalet) ; Vidal, A. (Centro de Investigacion Biomedica en Red Cancer (CIBERONC)) ; Martínez-Iniesta, M. (Program Against Cancer Therapeutic Resistance (ProCURE). Catalan Institute of Oncology (ICO). Bellvitge Institute for Biomedical Research (IDIBELL). Oncobell Program. L'Hospitalet del Llobregat) ; Martín-Tejera, J.F. (Program Against Cancer Therapeutic Resistance (ProCURE). Catalan Institute of Oncology (ICO). Bellvitge Institute for Biomedical Research (IDIBELL). Oncobell Program. L'Hospitalet del Llobregat) ; Villanueva, A. (Program Against Cancer Therapeutic Resistance (ProCURE). Catalan Institute of Oncology (ICO). Bellvitge Institute for Biomedical Research (IDIBELL). Oncobell Program. L'Hospitalet del Llobregat) ; Arias, A. (VHIO) ; Cuartas, I. (VHIO) ; Aransay, A.M. (Centro de Investigación Bimédica en Red de Enfermedades hepáticas y Digestivas (CIBERehd). CIC bioGUNE) ; La Madrid, A.M. (Pediatric Neuro-Oncology Unit. Department of Pediatric Hematology and Oncology. Hospital Sant Joan de Déu) ; Carcaboso, A.M. (Preclinical Therapeutics and Drug Delivery Research Program. Fundacio Sant Joan de Deu) ; Santa-Maria, V. (Pediatric Neuro-Oncology Unit. Department of Pediatric Hematology and Oncology. Hospital Sant Joan de Déu) ; Mora, J. (Department of Pediatric Hematology and Oncology. Hospital Sant Joan de Déu) ; Fernandez, A.F. (Institute of Oncology of Asturias (IUOPA). Instituto de Investigación Sanitaria del Principado de Asturias (ISPA-FINBA)) ; Fraga, M.F. (Nanomaterials and Nanotechnology Research Center (CINN-CSIC). Universidad de Oviedo-Principado de Asturias) ; Aldecoa, I. (Pathology-Brain Bank. Hospital Clínic de Barcelona-CDB-August Pi i Sunyer Biomedical Research Institute (IDIBAPS)) ; Pedrosa, L. (Glioma and Neural Stem Cell Group and Translational Genomics and Targeted Therapeutics in Solid Tumors Team. IDIBAPS) ; Graus Ribas, Francesc (Clinical and Experimental Neuroimmunology. IDIBAPS) ; Vidal, N. (Department of Pathology. Hospital Universitari de Bellvitge. IDIBELL. L'Hospitalet del Llobregat) ; Martínez-Soler, F. (Faculty of Medicine and Health Sciences-Bellvitge. Universitat de Barcelona. IDIBELL. L'Hospitalet del Llobregat) ; Tortosa, A. (Faculty of Medicine and Health Sciences-Bellvitge. Universitat de Barcelona. IDIBELL. L'Hospitalet del Llobregat) ; Carrato, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Balañá, Carmen (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Boudreau, M.W. (Department of Chemistry. University of Illinois at Urbana-Champaign) ; Hergenrother, P.J. (Department of Chemistry. University of Illinois at Urbana-Champaign) ; Kötter, P. (Institute for Molecular Biosciences. Goethe University) ; Entian, K.D. (Institute for Molecular Biosciences. Goethe University) ; Hench, J. (Division of Neuropathology. Institute of Medical Genetics and Pathology. University Hospital Basel) ; Frank, S. (Division of Neuropathology. Institute of Medical Genetics and Pathology. University Hospital Basel) ; Mansouri, S. (Division of Neurosurgery. Toronto Western Hospital. University of Toronto) ; Zadeh, G. (Division of Neurosurgery. Toronto Western Hospital. University of Toronto) ; Dans, P.D. (Joint IRB-BSC Program on Computational Biology. Institute for Research in Biomedicine (IRB Barcelona). The Barcelona Institute of Science and Technology (BIST)) ; Orozco, M. (Department of Biochemistry and Biomedicine. University of Barcelona) ; Thomas, G. (Division of Hematology/Oncology. Department of Internal Medicine. University of Cincinnati Medical School) ; Blanco, S. (Molecular Mechanisms Program. Centro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer. Consejo Superior de Investigaciones Científicas (CSIC). University of Salamanca) ; Seoane, J. (Institució Catalana de Recerca i Estudis Avançats (ICREA)) ; Preiss, T. (Victor Chang Cardiac Research Institute) ; Pandolfi, P.P. (Department of Medicine and Pathology. Cancer Research Institute. Beth Israel Deaconess Cancer Center. Beth Israel Deaconess Medical Center. Harvard Medical School) ; Esteller, M. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Universitat Autònoma de Barcelona
Tumors have aberrant proteomes that often do not match their corresponding transcriptome profiles. One possible cause of this discrepancy is the existence of aberrant RNA modification landscapes in the so-called epitranscriptome. [...]
2019 - 10.1007/s00401-019-02062-4  
3.
11 p, 2.4 MB Oncometabolic nuclear reprogramming of cancer stemness / Menendez, Javier A. (Institut Català d'Oncologia) ; Corominas-Faja, Bruna (Institut d'Investigació Biomèdica de Girona) ; Cuyàs, Elisabet (Institut d'Investigació Biomèdica de Girona) ; García, María G. (Instituto Universitario de Oncología del Principado de Asturias) ; Fernández-Arroyo, Salvador (Hospital Universitari de Sant Joan) ; Fernández, Agustín F. (Instituto Universitario de Oncología del Principado de Asturias) ; Joven, Jorge (Hospital Universitari de Sant Joan) ; Fraga, Mario F. (Instituto Universitario de Oncología del Principado de Asturias) ; Alarcón Cor, Tomás (Centre de Recerca Matemàtica)
By impairing histone demethylation and locking cells into a reprogramming-prone state, oncometabolites can partially mimic the process of induced pluripotent stem cell generation. Using a systems biology approach, combining mathematical modeling, computation, and proof-of-concept studies with live cells, we found that an oncometabolite-driven pathological version of nuclear reprogramming increases the speed and efficiency of dedifferentiating committed epithelial cells into stem-like states with only a minimal core of stemness transcription factors. [...]
2016 - 10.1016/j.stemcr.2015.12.012
Stem cell reports, Vol. 6, issue 3 (March 2016) , p. 273-283  
4.
17 p, 3.5 MB Development Refractoriness of MLL-Rearranged Human B Cell Acute Leukemias to Reprogramming into Pluripotency / Muñoz López, Álvaro (Universitat de Barcelona (Campus Clínic). Institut de Recerca contra la Leucèmia Josep Carreras) ; Romero Moya, Damià (Universitat de Barcelona (Campus Clínic). Institut de Recerca contra la Leucèmia Josep Carreras) ; Prieto, Cristina (Universitat de Barcelona (Campus Clínic). Institut de Recerca contra la Leucèmia Josep Carreras) ; Ramos Mejía, Verónica (Centro Pfizer - Universidad de Granada - Junta de Andalucía de Genómica e Investigación Oncológica) ; Agraz Doblas, Antonio (Universitat de Barcelona (Campus Clínic). Institut de Recerca contra la Leucèmia Josep Carreras) ; Varela, Ignacio (Instituto de Biomedicina y Biotecnología de Cantabria) ; Buschbeck, Marcus (Universitat de Barcelona (Campus Clínic). Institut de Recerca contra la Leucèmia Josep Carreras) ; Palau, Anna (Universitat de Barcelona (Campus Clínic). Institut de Recerca contra la Leucèmia Josep Carreras) ; Carvajal Vergara, Xonia (Universidad de Navarra. Centro de Investigación Médica Aplicada) ; Giorgetti, Alessandra (Universitat de Barcelona (Campus Clínic). Institut de Recerca contra la Leucèmia Josep Carreras) ; Ford, Anthony (Institute of Cancer Research (London, Gran Bretanya)) ; Lako, Majlinda (Newcastle University. Institute of Genetic Medicine) ; Granada i Font, Isabel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Ruiz Xivillé, Neus (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Rodríguez Perales, Sandra (Centro Nacional de Investigaciones Oncológicas) ; Torres Ruíz, Raúl (Universitat de Barcelona (Campus Clínic). Institut de Recerca contra la Leucèmia Josep Carreras) ; Stam, Ronald W. (Erasmus University Medical Center (Rotterdam, Holanda)) ; Fuster, José Luis (Hospital Clínico Universitario Virgen de la Arrixaca (El Palmar, Múrcia)) ; Fraga, Mario F. (Instituto Universitario de Oncología del Principado de Asturias (Oviedo)) ; Nakanishi, Mahito (National Institute of Advanced Industrial Science and Technology (Tsukuba, Japó)) ; Cazzaniga, Gianni (Università degli Studi di Milano-Bicocca) ; Bardini, Michela (Università degli Studi di Milano-Bicocca) ; Cobo, Isabel (Universitat de Barcelona (Campus Clínic). Institut de Recerca contra la Leucèmia Josep Carreras) ; Bayón, Gustavo F. (Instituto Universitario de Oncología del Principado de Asturias (Oviedo)) ; Fernández, Agustín F. (Instituto Universitario de Oncología del Principado de Asturias (Oviedo)) ; Bueno, Clara (Universitat de Barcelona (Campus Clínic). Institut de Recerca contra la Leucèmia Josep Carreras) ; Menéndez, Pablo (Universitat de Barcelona (Campus Clínic). Institut de Recerca contra la Leucèmia Josep Carreras)
Induced pluripotent stem cells (iPSCs) are a powerful tool for disease modeling. They are routinely generated from healthy donors and patients from multiple cell types at different developmental stages. [...]
2016 - 10.1016/j.stemcr.2016.08.013
Stem cell reports, Vol. 7 Núm. 4 (October 2016)  

See also: similar author names
2 Fraga, Mar
4 Fraga, Mario F.
1 Fraga, María Jesús
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.